ASX ANNOUNCEMENT **5 June 2026**

NOT FOR RELEASE TO US WIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES

EBR Systems successfully completes Institutional Placement and Institutional Entitlement Offer

Key Highlights:

- EBR has successfully completed its fully underwritten placement ("**Institutional Placement**") and institutional component ("**Institutional Entitlement Offer**") of its 1 for 2 accelerated non-renounceable entitlement offer of new CHESS Depositary Interests ("**New CDIs**") in EBR ("**Entitlement Offer**") announced on Thursday, 4 June 2026 ("**Capital Raising**").
- The Institutional Placement received strong support from both existing and new eligible securityholders, raising approximately $64.4 million. Of this, $29.4 million will be raised under tranche 1 of the Institutional Placement, which does not require securityholder approval ("**Tranche 1 Placement**"), and $35.0 million will be raised under the second tranche of the Institutional Placement, which is subject to securityholder approval at a special meeting of securityholders ("**Tranche 2 Placement**").
- The Institutional Entitlement Offer raised gross proceeds of $42.0 million with a take up of $8.4m by eligible institutional securityholders and the remainder of the institutional entitlements being $33.6 million, including New CDIs not taken up by foreign ineligible security holders, were placed to eligible institutional and sophisticated investors as part of the bookbuild.
- Certain funds that are existing securityholders and advised by Brandon Capital have subscribed for $35.0 million of New CDIs under the Tranche 2 Placement and $11.65 million of sub-underwriting of the Retail Entitlement Offer.
- The Retail Entitlement Offer to raise a further ~$43.6 million will open on Thursday, 11 June 2026 to Eligible retail securityholders with a registered address in Australia and New Zealand as at the Record Date.
- The Tranche 1 Placement and the Institutional Component of the Entitlement Offer is expected to settle on Thursday, 11 June 2026.
- The Tranche 2 Placement to raise $35.0m, which is subject to security holder approval at a company general meeting, is expected to settle in August 2026.

Sunnyvale, California; 5 June 2026: EBR Systems, Inc. (ASX: "**EBR**", "**EBR Systems**" or the "**Company**") developer of the world's only wireless cardiac pacing device for heart failure, is today pleased to announce it has successfully completed its Institutional Placement and the Institutional Entitlement Offer, announced on Thursday, 4 June 2026.

The Institutional Placement and Institutional Entitlement Offer will raise approximately A$106.4 million in total at an issue price of A$0.38 per New CDI ("**Offer Price**"), consisting of approximately A$29.4 million under the Tranche 1 Placement, A$35.0m under the Tranche 2 Placement (subject to securityholder approval at the EGM) and A$42.0 million under the Institutional Entitlement Offer.

The New CDIs subscribed for under the Tranche 1 Placement and the Institutional Entitlement Offer are expected to be settled on Thursday, 11 June 2026 and be issued and commence trading on ASX, on Friday, 12 June 2026.

As a result of the successful completion of the Tranche 1 Placement and the Institutional Entitlement Offer, the Company expects ASX to lift the trading halt and the Company's CDIs to recommence normal trading on an ex entitlement basis on Friday, 5 June 2026.

Canaccord Genuity (Australia) Limited, E&P Capital Limited and Morgans Corporate Limited are acting as joint underwriters, joint lead managers and joint bookrunners for the Capital Raising (**Joint Lead Managers**).

Retail Entitlement Offer

The retail component of the Entitlement Offer ("**Retail Entitlement Offer**") will open at 9:00am (Sydney time) on Thursday, 11 June 2026 and close at 5:00pm (Sydney time) on Monday, 22 June 2026. Approximately A$43.6 million is able to be raised under the Retail Entitlement Offer. The Retail Entitlement Offer is fully underwritten.

The Retail Entitlement Offer will be made to all securityholders ("**Eligible Retail Securityholders**") who:

- are registered as holders of CDIs as at 7.00pm (Sydney time) on Friday, 5 June 2026 (being the Record Date);
- have a registered address on EBR's CDI register in Australia or New Zealand;
- are not in the United States and are not a person (including nominees or custodians) acting for the account or benefit of a person in the United States;
- were not invited to participate in the Institutional Entitlement Offer and were not treated as an ineligible institutional securityholder under the Institutional Entitlement Offer; and
- are eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer.

Securityholders with a registered address outside Australia or New Zealand are considered ineligible securityholders and cannot participate in the Retail Entitlement Offer.

Further details about the Retail Entitlement Offer will be contained in the Retail Entitlement Offer Booklet, which is expected to be lodged on ASX on Thursday, 11 June 2026 (Sydney time). Eligible Retail Securityholders wishing to participate in the Retail Entitlement Offer should carefully read the Retail Entitlement Offer Booklet before making any investment decision regarding the Retail Entitlement Offer.

Key Dates for Entitlement Offer*:

Event	**Date**
Announce placement and accelerated non-renounceable entitlement offer (**ANREO)**	Thursday, 4 June 2026
Announcement of results of Placement and Institutional Entitlement Offer Resumption of trading on the ASX	Friday, 5 June 2026
ANREO Record Date (7:00pm)	Friday, 5 June 2026
Retail Entitlement Offer opens and retail offer booklet dispatched	Thursday, 11 June 2026
Settlement of Securities under the Institutional Entitlement Offer, Institutional Bookbuild and Tranche 1 of the Placement	Thursday, 11 June 2026
Allotment of Securities under the Institutional Entitlement Offer, Institutional Bookbuild and Tranche 1 of the Placement	Friday, 12 June 2026
Normal trading of New Securities under the Institutional Entitlement Offer, Institutional Bookbuild and Tranche 1 of the Placement	Monday, 15 June 2026
Retail Entitlement Offer closes	5pm on Monday, 22 June 2026
Announcement of results of Retail Entitlement Offer	Wednesday, 24 June 2026
Settlement of Retail Entitlement Offer	Friday, 26 June 2026
Allotment of Securities issued under the Retail Entitlement Offer	Monday, 29 June 2026

Normal trading of Securities issued under the Retail Entitlement Offer	Tuesday, 30 June 2026
EGM for Tranche 2 of the Placement	August 2026
Settlement of Securities issued under Tranche 2 of the Placement	August 2026
Allotment of Securities issued under Tranche 2 of the Placement	August 2026

*Please note the dates set out above are indicative only and are subject to change. All dates and times are references to Sydney, Australia time.

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 (**US Securities Act**) and may not be offered or sold in the United States or to US persons except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

This announcement has been authorised for release by the Board of Directors of EBR Systems, Inc.

ENDS

For more information, please contact:

Company
Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: info@ebrwise.com

Investor Relations
Gabriella Hold
The Capital Network
P: +61 2 8999 3699
E: gaby@thecapitalnetwork.com.au

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.